Scroll to the bottom of the page to pay your bill

Managing Oligometastatic Lung Cancer

Oligometastatic lung cancer is cancer that has spread from the primary location to one or a few other organs. In most cases, oligometastatic lung disease occurs in the brain. Synchronous oligomestatases can occur during the initial diagnosis, while metachronousoligometastases are seen within six months of diagnosis. The oligometastatic phenotype is typically a function of the current biology of cancer in the body.

In several clinical trials to manage oligometastatic lung cancer:

 Oligometastatic non-small cell lung cancer patients who received locally ablative therapy after systematic therapy showed improvement in their progression-free survival and overall survival.

 It was noted that most of the patients who benefited from this trial were those with 0 to 1 metastatic lesion.

 In a screening study, patients with up to 5 metastatic foci in different types of cancers were given definitive treatment and standardized palliative therapy with stereotactic radiotherapy. Improvement in progression-free survival and overall survival was observed in this group as well. A randomized clinical trial is underway to confirm these results.

 Another trial was conducted to assess the outcomes in patients with oligometastatic lung cancer when immunotherapy is added to locally ablative therapy. The patients were given pembrolizumab (Keytruda) for six months with excellent results.

These few trials and many others have confirmed that locally ablative therapy can be used as a treatment option for oligometastatic lung disease. As for immunotherapy, efforts are ongoing to help identify its biomarkers to help direct oncologists on the right patients who can receive the combination with definitive results.

Currently, randomized trials are being carried out to evaluate the efficacy of locally ablative therapy in treating oligometastatic lung cancer. Also, the role of immunotherapy has to be confirmed in such a setting to help improve outcomes for patients. Clinicians now have an essential job of identifying which patients can benefit from this therapy.

You Might Also Enjoy...

Are You at Risk for Ovarian Cancer?

It would be great if we had a crystal ball to tell us which illnesses we’ll get and how to avoid them. Until we do, the next best thing is to know your risk factors for certain diseases, including ovarian cancer.

How MammoSite® Therapy Works

After your breast cancer diagnosis, your mind turns immediately to treatments. You want the most effective, least invasive option possible. Here’s why MammoSite® targeted radiation therapy may be the best answer.

How Long Does Hair Loss Last With Chemo or Radiation?

You’d give up almost anything for a chance to beat your cancer. And many treatments will test your resolve to do just that. Hair loss is one of the sacrifices most-often associated with chemo and radiation. Here’s what you can expect.

How Hormone Therapy Works to Combat Cancer

Most people are familiar with radiation and chemotherapy as effective go-to treatments, but there are many more cancer-fighting weapons in our arsenal. Here’s how hormone therapy may be a key player in your cancer treatment plan.